24-Apr-2015 - MYMETICS Corporation

Mymetics-Led Consortium Awarded €8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines

Mymetics Corporation  announced that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to €3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grants will fund the evaluation, development and manufacturing scale-up of thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates.

Of the total amount, €3.4 million is directly attributable to Mymetics activities, with the balance going to the consortium partners, Catalent UK Swindon Zydis Ltd, Chimera Biotec GmbH (Germany), Upperton Ltd. (UK) and Bachem AG (Switzerland).

“With more than 90% of the existing vaccines dependent on the cold-chain and the resulting detrimental impact on availability, efficacy and costs of these vaccines in developing countries, there is an undisputable need to innovate and manufacture vaccines that are stable and temperature independent” commented Ronald Kempers, CEO of Mymetics. “We are very pleased that our virosome vaccine technology and know-how has been recognized together with the skills and expertise of our EU consortium partners.  Funding this project can represent a major innovation in vaccine development.”

The EU Horizon 2020 project is named MACIVIVA, which stands for “Manufacturing process for Cold-chain Independent Virosome-based Vaccines”. The project duration is in total 3.5 years and brings together the leading contract manufacturers and the relevant expertise for spray drying, freeze drying and analytical techniques from the pharmaceutical industry to develop a scalable manufacturing process to achieve thermo stable and cold-chain independent virosome based vaccines.

Dr. Sylvain Fleury, Mymetics CSO and overall MACIVIVA project coordinator stated, “We are very thankful for the EU Horizon 2020 and Swiss funding organizations to finance this very important innovation project in the world of vaccines. We look forward to work with our consortium partners to start the efforts on our promising virosome-based HIV vaccine candidate, with the overall objective to make this scalable and applicable for all our virosome based vaccines”.

The MACIVIVA project will receive €5.3 million funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 646122.

Facts, background information, dossiers
  • Upperton
  • Bachem
  • Catalent
  • Chimera Biotec
More about Catalent Pharma Solutions
  • News

    Catalent Invests $7.3 Million in Italy

    Catalent Pharma Solutions announced that it had completed the first phase of a $7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy. The first phase of investment, completed in August 2018, saw the expansion and ... more

    Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars

    Catalent Pharma Solutions and Valerius Biopharma AG, a Swiss biopharmaceutical company dedicated to providing interchangeable treatment options for high-priced orphan and non-orphan biologics, announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar ... more

    BASF and Catalent join forces to solve bioavailability challenges

    Catalent Pharma Solutions and BASF have entered into a broad collaboration and Open Alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges. The companies aim to combine their expertise to provide pharmaceutic ... more

  • Companies

    Catalent Pharma Solutions

    Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalen ... more

More about Chimera Biotec
More about Upperton
More about Bachem
  • News

    Change on the Bachem Corporate Executive Committee

    Bachem announced that Dr. Thomas Früh will be stepping down as CEO on health grounds effective January 1, 2020. Dr. Früh will continue to serve the company in a corporate services role. His successor as CEO will be current Chief Operations Officer (COO) and Corporate Executive Committee mem ... more

    Thomas Meier to become new COO of Bachem Group

    Bachem announced that Thomas Meier will succeed Dr. Alex Fässler as Chief Operations Officer of Bachem Group with effect from January 1, 2019. Dr. Alex Fässler will retire at the end of April 2019 yet will continue to serve the company in an advisory capacity. Thomas Meier was born in 1968 ... more

    Bachem to expand in asian markets

    Bachem announces the establishment of Bachem Japan K.K., a subsidiary in Tokyo, Japan. This new local presence in Asia will strengthen project and customer support and drive further business growth in the Asian market."This is an exciting step for Bachem", comments Dr. Anne-Kathrin Stoller, ... more

  • Videos

    Corporate Video Bachem AG


  • Companies

    Bachem AG

    Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based acti ... more

    Bachem Distribution Services GmbH

    Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as ... more